Companies Selling Supplements With Claims to Treat CVD Get Hit With Warning Letters

These dietary supplements have not been evaluated by the FDA for safety or effectiveness.

Warning letters were issued by the Food and Drug Administration (FDA) to 7 companies for illegally selling dietary supplements claiming to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure. 

According to the FDA, the following companies have received warning letters for illegally selling these dietary supplements:

These dietary supplements have not been evaluated by the FDA to be safe or effective. The FDA is advising consumers not to use these products due to the potential harm they may cause. Health care providers and consumers are encouraged to report adverse events related to these unapproved products to the FDA’s MedWatch Adverse Event Reporting program or the Safety Reporting Portal.

“We encourage consumers to remain vigilant when shopping online or in stores to avoid purchasing products that could put their health at risk,” said Cara Welch, PhD, director of the Office of Dietary Supplement Programs in the FDA’s Center for Food Safety and Applied Nutrition. “Dietary supplements that claim to cure, treat, mitigate or prevent cardiovascular disease and related conditions could potentially harm consumers who use these products instead of seeking safe and effective FDA-approved treatments from qualified health care providers.”

A recent study presented at the American Heart Association’s Scientific Sessions 2022 showed that compared with placebo, none of the dietary supplements included in the analysis demonstrated a significant decrease in low-density lipoprotein cholesterol, total cholesterol, or triglycerides. A low-dose statin was found to be more effective than 6 commonly used cholesterol health supplements.


FDA warns seven companies for selling dietary supplements with claims to treat cardiovascular disease. News release. US Food and Drug Administration. Accessed November 17, 2022.

This article originally appeared on MPR